Kathryn Heins-Erickson, APRN
Adult Health · Clay Center, KSNPI 1861852469
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 92.7% of the total across 71 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 17 manufacturers reported payments, led by Mylan Specialty L.p. at 34.2% of the total. Reporting peaked in 2022 at $474 and has fallen 83.2% since, to $80 in 2025.
Across 71 payments — averaging $19.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mylan Specialty L.p.$470
- Lilly USA, LLC$154
- Amgen$142
- Harmony Biosciences LLC$120
- AstraZeneca$80
- Amarin Pharma, Inc.$79
- plus $329 from 11 others
What the payments were for
- Food & beverage$1,27393%
- Education$1007%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Mylan Specialty L.p. | 26 | $470 |
| Lilly USA, LLC | 9 | $154 |
| Amgen | 6 | $142 |
| Harmony Biosciences LLC | 2 | $120 |
| AstraZeneca | 5 | $80 |
| Amarin Pharma, Inc. | 4 | $79 |
| Novartis | 4 | $71 |
| Dexcom, Inc. | 2 | $39 |
| Boehringer Ingelheim | 2 | $39 |
| Bayer | 3 | $38 |
| Esperion Therapeutics, Inc. | 2 | $33 |
| Viatris Specialty LLC | 1 | $25 |
| Xeris Pharmaceuticals, Inc. | 1 | $19 |
| AbbVie | 1 | $19 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $17 |
| Jazz Pharmaceuticals Inc. | 1 | $17 |
| Johnson & Johnson | 1 | $13 |
How this compares
$1,373 in reported general payments places this provider in the 70th percentile of 155 adult health providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 33 | $36,218 |
| JardianceEmpagliflozin | 50 | $34,701 |
| EliquisApixaban | 43 | $19,639 |
| TrulicityDulaglutide | 17 | $15,968 |
| EntrestoSacubitril/Valsartan | 20 | $9,979 |
| Repatha SureclickEvolocumab | 11 | $9,894 |
| Aimovig AutoinjectorErenumab-Aooe | 13 | $9,625 |
| Tresiba Flextouch U-200Insulin Degludec | 16 | $9,347 |
| XareltoRivaroxaban | 15 | $9,108 |
| FarxigaDapagliflozin Propanediol | 16 | $8,354 |
| Tresiba Flextouch U-100Insulin Degludec | 15 | $7,435 |
| Dexlansoprazole DrDexlansoprazole | 11 | $2,652 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 13 | $1,686 |
| Ezetimibe | 162 | $1,582 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 114 | $1,486 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $154 | $52,18650 claims |
| Boehringer IngelheimJardiance | $39 | $34,70150 claims |
| NovartisEntresto | $71 | $9,97920 claims |
| Johnson & JohnsonXarelto | $13 | $9,10815 claims |
| AstraZenecaFarxiga | $80 | $8,35416 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 155 adult health providers in Kansas.
Other adult health in Clay Center
- Valerie DavisWichita$100K
- Julianna BergkampWichita$18K
- Lauren FieldsOverland Park$12K
- Tina LegaultOverland Park$12K
- Candace KoirthPratt$11K
- Jennifer SurpriseKansas City$8K
- Angela leWichita$7K
- Monica PfeifferOverland Park$7K
- Amy RiederOverland Park$6K
- Jenny PearsonKansas City$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.